France
· Delayed Price · Currency is EUR MedinCell Statistics
Total Valuation
MedinCell has a market cap or net worth of EUR 474.10 million. The enterprise value is 504.44 million.
| Market Cap | 474.10M |
| Enterprise Value | 504.44M |
Important Dates
The next estimated earnings date is Tuesday, June 17, 2025.
| Earnings Date | Jun 17, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
MedinCell has 29.23 million shares outstanding. The number of shares has increased by 9.39% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 29.23M |
| Shares Change (YoY) | +9.39% |
| Shares Change (QoQ) | +0.44% |
| Owned by Insiders (%) | 15.77% |
| Owned by Institutions (%) | 27.60% |
| Float | 21.04M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 60.64 |
| PS Ratio | 35.68 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 22.54 |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -16.04 |
| EV / Sales | 38.22 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 23.99 |
Financial Position
The company has a current ratio of 1.46
| Current Ratio | 1.46 |
| Quick Ratio | 1.41 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | 3.29 |
| Interest Coverage | -4.14 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -22.38% |
| Return on Capital (ROIC) | -44.12% |
| Revenue Per Employee | 100,763 |
| Profits Per Employee | -240,061 |
| Employee Count | 134 |
| Asset Turnover | 0.24 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +101.23% in the last 52 weeks. The beta is 1.22, so MedinCell's price volatility has been higher than the market average.
| Beta (5Y) | 1.22 |
| 52-Week Price Change | +101.23% |
| 50-Day Moving Average | 17.02 |
| 200-Day Moving Average | 15.56 |
| Relative Strength Index (RSI) | 43.84 |
| Average Volume (20 Days) | 54,831 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, MedinCell had revenue of EUR 13.20 million and -31.45 million in losses. Loss per share was -1.08.
| Revenue | 13.20M |
| Gross Profit | 13.20M |
| Operating Income | -19.58M |
| Pretax Income | -31.23M |
| Net Income | -31.45M |
| EBITDA | -18.81M |
| EBIT | -19.58M |
| Loss Per Share | -1.08 |
Balance Sheet
The company has 38.85 million in cash and 69.19 million in debt, giving a net cash position of -30.34 million or -1.04 per share.
| Cash & Cash Equivalents | 38.85M |
| Total Debt | 69.19M |
| Net Cash | -30.34M |
| Net Cash Per Share | -1.04 |
| Equity (Book Value) | -54.03M |
| Book Value Per Share | -1.86 |
| Working Capital | 15.10M |
Cash Flow
In the last 12 months, operating cash flow was 21.40 million and capital expenditures -367,000, giving a free cash flow of 21.03 million.
| Operating Cash Flow | 21.40M |
| Capital Expenditures | -367,000 |
| Free Cash Flow | 21.03M |
| FCF Per Share | 0.72 |
Margins
Gross margin is 100.00%, with operating and profit margins of -148.34% and -238.24%.
| Gross Margin | 100.00% |
| Operating Margin | -148.34% |
| Pretax Margin | -236.60% |
| Profit Margin | -238.24% |
| EBITDA Margin | -142.50% |
| EBIT Margin | -148.34% |
| FCF Margin | 159.31% |
Dividends & Yields
MedinCell does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -9.39% |
| Shareholder Yield | -9.39% |
| Earnings Yield | -6.68% |
| FCF Yield | 4.44% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
MedinCell has an Altman Z-Score of 0.8. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.8 |
| Piotroski F-Score | n/a |